Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

Weight loss from glucagon-like peptide 1 agonists clearly alleviates knee osteoarthritis pain, but other recently published data give pause regarding possible long-term adverse effects.

Novo Nordisk rejoined the ABPI after a two-year suspension linked to promotional concerns. Audits confirmed compliance with ...

Neoadjuvant semaglutide before metabolic and bariatric surgery (MBS) is not beneficial in terms of weight loss.

Allurion Technologies' gastric balloon and Novo Nordisk's semaglutide achieved 20.3% weight loss in a trial. Read more here.

No benefits seen in terms of weight loss, diabetes remission, surgery safety. (HealthDay News) — Neoadjuvant semaglutide before metabolic and bariatric surgery (MBS) is not beneficial in terms ...

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

He and his team then compared the diagnoses for hair loss in these patients’ medical records and found that those prescribed ...

“Many of our nondiabetic patients do lose the weight described in the clinical study. Zepbound as well as semaglutide [drugs] have been effective for weight loss for patients. The weight ...

The company could continue to offer more personalized semaglutide formulations and shift its focus to older generic weight-loss drugs. Additionally, on Tuesday Bank of America Securities (BAC ...